Olopatadine nasal spray for the treatment of allergic rhinitis

被引：4

作者：

Roland, Peter S. ^{[1
]}

Marple, Bradley F. ^{[2
]}

Wall, G. Michael ^{[3
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Dept Otolaryngol, Dallas, TX 75390 USA

[2] Univ Texas SW Med Ctr Dallas, Dept Otolaryngol Head & Neck Surg, Dallas, TX 75390 USA

[3] Alcon Res Ltd, Ft Worth, TX 76134 USA

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2010年 / 6卷 / 02期

关键词：

allergic rhinitis; allergic rhinosinusitis; antihistamine; mast cell stabilizer; nasal spray; olopatadine hydrochloride; Patanase (R); SUBLINGUAL IMMUNOTHERAPY; HYDROCHLORIDE; EFFICACY; SAFETY; EPIDEMIOLOGY;

D O I：

10.1586/ECI.09.89

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Olopatadine hydrochloride nasal spray (Patanase(R) Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H-1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

引用

页码：197 / 204

页数：8

共 34 条

[1] Mechanisms and treatment of allergic disease in the big picture of regulatory T cells [J].

Akdis, Cezmi A. ;

Akdis, Muebeccel .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (04) :735-746

[2] Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation [J].

Bohle, Barbara ;

Kinaciyan, Tamar ;

Gerstmayr, Marianne ;

Radakovics, Astrid ;

Jahn-Schmid, Beatrice ;

Ebner, Christof .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 120 (03) :707-713

[3]

BOSQUET J, 2007, GLOBAL SURVEILLANCE

[4] Allergic rhinitis and its impact on asthma [J].

Bousquet, J ;

van Cauwenberge, P ;

Khaltaev, N ;

Ait-Khaled, N ;

Annesi-Maesano, I ;

Bachert, C ;

Baena-Cagnani, C ;

Bateman, E ;

Bonini, S ;

Canonica, GW ;

Carlsen, KH ;

Demoly, P ;

Durham, SR ;

Enarson, D ;

Fokkens, WJ ;

van Wijk, RG ;

Howarth, P ;

Ivanova, NA ;

Kemp, JP ;

Klossek, JM ;

Lockey, RF ;

Lund, V ;

Mackay, I ;

Malling, HJ ;

Meltzer, EO ;

Mygind, N ;

Okunda, M ;

Pawankar, R ;

Price, D ;

Scadding, GK ;

Simons, FER ;

Szczeklik, A ;

Valovirta, E ;

Vignola, AM ;

Wang, DY ;

Warner, JO ;

Weiss, KB .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (05) :S147-S334

[5]

CLARK RR, 1998, J RESP DIS, V19, pS6

[6] Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis [J].

Creticos, Peter S. ;

Schroeder, John T. ;

Hamilton, Robert G. ;

Balcer-Whaley, Susan L. ;

Khattignavong, Arouna P. ;

Lindblad, Robert ;

Li, Henry ;

Coffman, Robert ;

Seyfert, Vicki ;

Eiden, Joseph J. ;

Broide, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1445-1455

[7] Sublingual immunotherapy [J].

Esch, Robert E. .

CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2008, 16 (03) :260-264

[8]

FAIRCHILD CJ, 2007, ALLERGY ASTHMA PROC, V28, P1

[9]

*GLAXOSMITHKLINE, 2007, VERAMYST NAS SPRAY P

[10] Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 μg in the treatment of seasonal allergic rhinitis [J].

Kaliner, Michael A. ;

Storms, William ;

Tilles, Stephen ;

Spector, Sheldon ;

Tan, Ricardo ;

LaForce, Craig ;

Lanier, Bobby Q. ;

Chipps, Bradley .

ALLERGY AND ASTHMA PROCEEDINGS, 2009, 30 (03) :255-262

← 1 2 3 4 →